439
|
1915 |
PLCG1
|
|
affects_quantity of
|
Phosphatidylinositol-4,5-bisphosphate
|
in pilocarpine model
|
1924 |
Phosphatidylinositol-4,5-bisphosphate
|
|
affects_activity of
|
Diacylglycerol
|
in pilocarpine model
|
1925 |
Phosphatidylinositol-4,5-bisphosphate
|
|
affects_activity of
|
Inositol 1,4,5-trisphosphate
|
in pilocarpine model
|
|
1471196
|
Status epilepticus
|
2,533
|
24149 |
Phosphatidylinositol-4,5-bisphosphate
|
|
affects_activity of
|
Gamma-secretase complex
|
in liposomes
|
24150 |
Phosphatidylinositol-4,5-bisphosphate
|
|
affects_quantity of
|
Amyloid beta peptide (42)
|
in cultured fibroblasts
|
|
21448224
|
Alzheimer disease
|
2,596
|
24508 |
Amyloid beta peptide (oligomer)
|
|
decreases_quantity of
|
Phosphatidylinositol-4,5-bisphosphate
|
|
24523 |
Phosphatidylinositol-4,5-bisphosphate
|
|
affects_activity of
|
Phosphatidylinositol-4,5-bisphosphate 5-phosphatase
|
|
24537 |
SYNJ1
|
|
affects_quantity of
|
Phosphatidylinositol-4,5-bisphosphate
|
in the brain and at the synapses
|
|
18391946
|
Alzheimer disease
|
4,329
|
44329 |
AGPAT2
|
|
increases_quantity of
|
Phosphatidylinositol-4,5-bisphosphate
|
|
|
22872237
|
Metabolic
Lipodystrophy
|
5,058
|
49754 |
PLCB2
|
|
decreases_quantity of
|
Phosphatidylinositol-4,5-bisphosphate
|
|
|
8245028
|
Neurological
|
6,492
|
61664 |
Inositol
|
|
increases_quantity of
|
Phosphatidylinositol-4,5-bisphosphate
|
|
61665 |
PLC
|
|
decreases_quantity of
|
Phosphatidylinositol-4,5-bisphosphate
|
|
62202 |
Phosphatidylinositol-4,5-bisphosphate
|
|
increases_quantity of
|
Diacylglycerol
|
|
62203 |
Phosphatidylinositol-4,5-bisphosphate
|
|
increases_quantity of
|
Inositol 1,4,5-trisphosphate
|
|
|
15471909
|
Metabolic
|
6,496
|
61697 |
Phosphatidylinositol-4,5-bisphosphate
|
|
interacts (colocalizes) with
|
KCNQ2
|
|
61704 |
Phosphatidylinositol-4,5-bisphosphate
|
|
increases_activity of
|
KCNQ2
|
|
|
24277843
|
Metabolic
|
6,579
|
62763 |
Phosphatidylinositol 3-kinase
|
|
decreases_quantity of
|
Phosphatidylinositol-4,5-bisphosphate
|
|
|
22363263
|
Metabolic
|
8,164
|
82179 |
Phosphatidylinositol-4,5-bisphosphate
|
|
decreases_activity of
|
MCOLN1
|
in lysosome
|
|
25668017
|
Metabolic
|
10,191
|
106043 |
Phosphatidylinositol-4,5-bisphosphate
|
|
interacts (colocalizes) with
|
SLC6A4 complex, oligomer
|
stabilization of the oligomeric SERT complexes is mediated by the direct binding to phosphoinositide phosphatidylinositol-4,5-biphosphate (PIP2)
|
106044 |
Phosphatidylinositol-4,5-bisphosphate
|
|
increases_activity of
|
SLC6A4 complex, oligomer
|
stabilization of the oligomeric SERT complexes is mediated by the direct binding to phosphoinositide phosphatidylinositol-4,5-biphosphate (PIP2)
|
106047 |
Phosphatidylinositol-4,5-bisphosphate
|
|
increases_quantity of
|
SLC6A4 complex, oligomer
|
stabilization of the oligomeric SERT complexes is mediated by the direct binding to PIP2
|
|
28102201
|
Neurological
Metabolic
|
11,157
|
112828 |
PIP4K2A
|
|
increases_quantity of
|
Phosphatidylinositol-4,5-bisphosphate
|
PI42A catalyzes the formation of phosphatidylinositol 4,5bisphosphate (PtdIns(4,5)P2), referred to as PIP2 which has been proposed as a key regulator of clathrin endocytosis
|
112829 |
Phosphatidylinositol-4,5-bisphosphate
|
|
affects_activity of
|
clathrin-dependent endocytosis
|
PI42A catalyzes PIP2 which has been proposed as a key regulator of clathrin endocytosis
|
|
27636840
|
Alzheimer disease
|
11,517
|
114942 |
APOE (isoform E4)
|
|
decreases_quantity of
|
Phosphatidylinositol-4,5-bisphosphate
|
in postmortem human brain tissues of ApoE4 carriers
|
114947 |
APOE (isoform E4)
|
|
decreases_quantity of
|
Phosphatidylinositol-4,5-bisphosphate
|
even in normal aged ApoE4 carriers
|
114953 |
sex, female
|
|
decreases_quantity of
|
Phosphatidylinositol-4,5-bisphosphate
|
brain PIP2 levels of female subjects were lower than those of male subjects in cohorts; the reduction of PIP2 levels over the course of disease development and progression was more closely correlated in female subjects than in the overall population
|
124742 |
female brain
|
|
decreases_quantity of
|
Phosphatidylinositol-4,5-bisphosphate
|
in female brains; compared to male brains
|
124743 |
male brain
|
|
increases_quantity of
|
Phosphatidylinositol-4,5-bisphosphate
|
in male brains; compared to female brains
|
|
26372964
|
Alzheimer disease
|
11,518
|
114943 |
APOE (isoform E4)
|
|
decreases_quantity of
|
Phosphatidylinositol-4,5-bisphosphate
|
in the brains of ApoE4 knock-in (KI) mice; compared to APOE3 counterparts
|
114946 |
decreased SYNJ1 expression
|
|
increases_quantity of
|
Phosphatidylinositol-4,5-bisphosphate
|
in the brains of ApoE4 knock-in (KI) mice; and rescues AD-related cognitive deficits in these mice
|
141817 |
SYNJ1
|
|
decreases_quantity of
|
Phosphatidylinositol-4,5-bisphosphate
|
in the brains of ApoE4 knock-in (KI) mice
|
|
26372964
|
Alzheimer disease
|
11,523
|
114993 |
Phosphatidylinositol-4,5-bisphosphate
|
|
interacts (colocalizes) with
|
SLC6A4
|
|
114994 |
Phosphatidylinositol-4,5-bisphosphate
|
|
increases_activity of
|
response to amphetamine
|
not being a requirement for neurotransmitter uptake
|
114998 |
Phosphatidylinositol-4,5-bisphosphate
|
|
increases_quantity of
|
Inositol 1,4,5-trisphosphate
|
PIP2 is the precursor of inositol triphosphate (IP3) resulting from cleavage by phospholipase C (PLC)
|
115000 |
Phosphatidylinositol-4,5-bisphosphate
|
|
increases_activity of
|
protein membrane anchor
|
serving as an anchor for protein kinase C
|
115001 |
Phosphatidylinositol-4,5-bisphosphate
|
|
affects_activity of
|
exocytosis
|
|
115003 |
Phosphatidylinositol-4,5-bisphosphate
|
NOT |
affects_activity of
|
SLC6A1
|
|
115024 |
Phosphatidylinositol
|
|
increases_quantity of
|
Phosphatidylinositol-4,5-bisphosphate
|
through sequential phosphorylation of phosphatidylinositol via PI-4 kinase and PIP-5 kinase
|
115025 |
Phosphatidylinositol-4,5-bisphosphate
|
|
increases_quantity of
|
Diacylglycerol
|
PIP2 is the precursor of DAG resulting from cleavage by phospholipase C (PLC)
|
115026 |
PLC
|
|
increases_processing of
|
Phosphatidylinositol-4,5-bisphosphate
|
resulting in DAG and IP3
|
115057 |
Phosphatidylinositol-4,5-bisphosphate
|
|
is localized in
|
membrane raft
|
enriched in membrane rafts
|
115058 |
Phosphatidylinositol-4,5-bisphosphate
|
|
affects_activity of
|
endocytosis
|
|
115059 |
Phosphatidylinositol-4,5-bisphosphate
|
|
affects_activity of
|
ion transmembrane transport
|
|
|
23798435
|
Metabolic
|
15,119
|
141699 |
Phosphatidylinositol-4,5-bisphosphate
|
|
affects_activity of
|
autophagy
|
via regulation of two essential steps of autophagy
|
141759 |
APOE (isoform E4)
|
|
decreases_quantity of
|
Phosphatidylinositol-4,5-bisphosphate
|
in postmortem human brain tissues of APOE4 carriers, in the brains of mice knocked in for human APOE4, as well as in primary neurons and astrocytes derived from these mice; compared with APOE3
|
141760 |
SYNJ1
|
|
decreases_quantity of
|
Phosphatidylinositol-4,5-bisphosphate
|
specifically degrading PI(4,5)P2
|
141765 |
decreased SYNJ1 level
|
|
increases_quantity of
|
Phosphatidylinositol-4,5-bisphosphate
|
in an AD mouse model and in APOE4 knock-in mice
|
141878 |
APOE (isoform E3)
|
|
increases_quantity of
|
Phosphatidylinositol-4,5-bisphosphate
|
in postmortem human brain tissues of APOE4 carriers, in the brains of mice knocked in for human APOE4, as well as in primary neurons and astrocytes derived from these mice; compared with APOE4
|
|
|
Alzheimer disease
|
15,290
|
144877 |
PIKFYVE
|
|
increases_quantity of
|
Phosphatidylinositol-4,5-bisphosphate
|
for initiation of autolysosome tubulation
|
144878 |
Phosphatidylinositol-4,5-bisphosphate
|
|
increases_activity of
|
initiation of autolysosome tubulation
|
|
|
|
Alzheimer disease
|